9.40 USD
▲-0.05+5.38%
盘后 8.90 -0.22%
2026-08-03
市值
$174.16M
市盈率
—
EPS
-5.66
股息率
—
52 周区间
7.12 – 20.56
成交量
264.91K
Beta
2.56
目标价
35.30
52W 低 7.1252W 高 20.56
价格走势
公司简介
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.